Literature DB >> 24801454

[Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options].

G J Molderings1, J Homann2, S Brettner3, M Raithel4, T Frieling5.   

Abstract

In the present paper clinical phenotypes, pathogenetic relationships, and diagnostic algorithms as well as therapeutic concepts of/for systemic mast cell activation disease are reviewed. The reader should be able to recognize and diagnose a systemic mast cell activation disease, as well as to counsel a personalized drug therapy. In the case of chronic multisystem polymorbidity systemic mast cell activation disease should be considered as a differential diagnosis at an early stage. In most cases, specific, little invasive investigations allow diagnosing the disease and, hence, an appropriate therapy can be initiated. © Georg Thieme Verlag KG Stuttgart · New York.

Mesh:

Substances:

Year:  2014        PMID: 24801454     DOI: 10.1055/s-0034-1370055

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  Idiopathic mast cell activation syndrome and radiation therapy: a case study, literature review, and discussion of mast cell disorders and radiotherapy.

Authors:  Robin E Landy; William C Stross; Jackson M May; Tasneem A Kaleem; Timothy D Malouff; Mark R Waddle; Laura A Vallow
Journal:  Radiat Oncol       Date:  2019-12-09       Impact factor: 3.481

2.  Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome.

Authors:  Rupert Conrad; Martin Mücke; Tobias Jürgen Schmidt; Julia Sellin; Gerhard J Molderings
Journal:  Orphanet J Rare Dis       Date:  2022-07-29       Impact factor: 4.303

Review 3.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.